# A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

> **NCT07279597** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Muscle-invasive Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** RC48-ADC + Toripalimab

## Key facts

- **NCT ID:** NCT07279597
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-12-10
- **Final completion:** 2028-08-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07279597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07279597, "A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07279597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*